SCHEMBL5714513

SCHEMBL5714513

Cc1cccc(CCN2CCN(C(=O)Oc3ccc(CCSc4nccn4C)cc3)CC2)n1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
ADORA3 P0DMS8 1/20 0.38
HTR2A P28223 1/20 0.38
HTR7 P34969 1/20 0.38
OPRM1 P35372 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37
TP53 P04637 2/20 0.37
THRB P10828 1/20 0.37
POLB P06746 2/20 0.37
FAAH O00519 2/20 0.36
LMNA P02545 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714995 0.95 SIGMAR1 (0.42) MAPTADORA3HTR2AHTR7OPRM1
SCHEMBL5714923 0.93 KMT2A (0.40) MAPTALDH1A1KMT2APOLB
SCHEMBL5715066 0.92 SMN1; SMN2 (0.45) ALDH1A1KMT2ATP53THRBPOLB
SCHEMBL5714465 0.89 TP53 (0.49) MAPTADORA3HTR2AHTR7OPRM1
SCHEMBL5714500 0.88 SMN1; SMN2 (0.43) ADORA3HTR2AHTR7OPRM1SIGMAR1
SCHEMBL5714485 0.87 NPC1 (0.38) MAPTADORA3HTR2AHTR7OPRM1
SCHEMBL5714153 0.86 MAPT (0.39) MAPTHTR2AALDH1A1KMT2APOLB
SCHEMBL5715124 0.86 TP53 (0.44) ADORA3HTR2AHTR7OPRM1SIGMAR1
SCHEMBL5714580 0.86 MAPT (0.39) MAPTADORA3HTR2AHTR7OPRM1
SCHEMBL5715305 0.85 POLB (0.43) ADORA3HTR2AHTR7OPRM1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL MAPT 4348/4885ADORA3 3862/4885HTR2A 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.